Can tracking thousands of patients unlock the secrets of rare EBV-driven blood cancers?
NCT ID NCT07727083
First seen Jul 27, 2026 · Last updated Aug 14, 2026 · Updated 3 times
Summary
This study follows 1,500 people with Epstein-Barr virus-positive T/NK-cell lymphoproliferative diseases — rare conditions where the virus drives abnormal immune cell growth. Researchers will collect medical history, treatment details, and blood samples to see how the diseases behave over time. No experimental treatment is given; the goal is to learn more about these illnesses and identify factors linked to better or worse outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- This research could uncover patterns and biomarkers that help doctors better predict how these rare diseases will progress and which treatments work best.
- What could go wrong
- As an observational study, it does not test any new treatment, so it cannot directly improve care. Results may take years to emerge.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGGRESSIVE NK-CELL LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immunotherapy combo may outperform chemo in rare lymphoma
- Massive T-Cell lymphoma database aims to unlock new insights
- Engineered donor cells take aim at tough blood cancers in early trial
- New drug duo shows promise for rare blood cancer
- Promising combo may slash radiation harm in rare lymphoma
- New hope for deadly lymphoma combo: drug cocktail targets both cancer and immune chaos